News
AMPE
--
0.00%
--
AMPE, TSLA among premarket losers
Ampio Pharmaceuticals (AMPE) -6%.Tesla (TSLA) -5% after Elon Musk tweeted "what we announce will not reach serious high-volume production until 2022" ahead of Battery Day Event.
Seekingalpha · 9h ago
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Sept. 22, 2020: COST, ALB, CRSR, BLNK, AMPE
Today's 5 Stock Ideas (First Day of Fall Edition):  Costco (COST) - An earnings play. Will report Q4 results after market close on Thursday. Albemarle (ALB) - A play on batteries for automotive
Benzinga · 9h ago
Ampio Pharma on go with inhaled Ampion study in COVID-19
Ampio Pharmaceuticals (AMPE) soars 28% premarket after receiving an an Investigational New Drug ((IND)) from the FDA, allowing the Company to proceed with clinical trials for the use of Ampion as an inhalation
Seekingalpha · 1d ago
FDA Grants IND, Approves Clinical Trial Protocol Of Inhaled Ampion For Coronavirus Patients With Respiratory Distress
FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress ENGLEWOOD, Colo., Sept. 21, 2020 /PRNewswire/—Ampio Pharmaceuticals, Inc. (NYSE:AMPE)
Benzinga · 1d ago
FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress
ENGLEWOOD, Colo., Sept. 21, 2020 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") announces the receipt of an Investigational New Drug ("IND") from the U.S. Food and Drug Administration ("FDA"), allowing the Company to proceed with clinical
PR Newswire · 1d ago
Ampion Phase I COVID-19 Patient Trial Results Featured on FOX News (Video)
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that Michael Roshon, MD, PhD, Chief of Staff at Penrose-St. Francis Hospital in Colorado Springs, Colorado, who
PR Newswire · 09/14 14:15
Ampio Reports Positive Results for Ampion Treatment in COVID-19 Patients
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced positive results in early trial for intravenous ("IV") AmpionTM treatment for COVID-19 patients. We
PR Newswire · 09/09 14:15
Ampio Reports Positive Results For Ampion Treatment In Coronvirus Patients
Ampio Reports Positive Results for Ampion Treatment in COVID-19 Patients ENGLEWOOD, Colo., Sept. 9, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE),a biopharmaceutical company focused on the
Benzinga · 09/09 13:15
Ampio Gives Update On Osteoarthritis Of Knee Clinical Trial; Co Says Will Remain Blind To Trial Data To Comply With FDA Guidance On Trials Affected By COVID-19 Pandemic
ENGLEWOOD, Colo., Sept. 4, 2020 /PRNewswire/ --Ampio Pharmaceuticals, Inc. (NYSE:AMPE),a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions
Benzinga · 09/04 13:18
Ampio Announces Enrollment Completion For Intravenous COVID-19 Clinical Trial
ENGLEWOOD, Colo., Sept. 4, 2020 /PRNewswire/ --Ampio Pharmaceuticals, Inc. (NYSE:AMPE),a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions
Benzinga · 09/04 13:16
Ampio Announces Enrollment Completion for Intravenous ("IV") COVID-19 Clinical Trial & Provides Update on Osteoarthritis of the Knee ("OAK") Clinical Trial
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following:
PR Newswire · 09/04 13:15
Ampio Provides Update on COVID-19 Clinical Trial Activities
PR Newswire · 08/19 13:00
Ampio Pharma launches early-stage study of Ampion in COVID-19
Ampio Pharmaceuticals (NYSEMKT:AMPE) initiates dosing patients in Phase 1 U.S. based clinical trial evaluating a 5-day intravenous Ampion treatment for COV
seekingalpha · 07/23 18:19
Mid-Morning Market Update: Markets Down; AT&T Earnings Beat Estimates
Following the market opening Thursday, the Dow traded down 0.26% to 26,936.51 while the NASDAQ fell 0.11% to 10,692.02. The S&P also fell, dropping 0.04% to 3,274.73.
Benzinga · 07/23 14:13
Ampio Starts Patient Enrollment in its Ampion COVID-19 Program
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is
PR Newswire · 07/23 12:00
Ampio Reports a Publication on the Potential Benefits of Ampion for Treatment of a New COVID-19 related Syndrome
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development and advancement of immunology based therapies for prevalent inflammatory conditions, today announced the publication "Insights into pediatric multi-system
PR Newswire · 07/20 12:00
Ampio Pharmaceuticals (AMPE) Jumps: Stock Rises 8.7%
Zacks · 06/29 16:31
Regeneron's Latest Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/22 18:54
Ampio to Start First Clinical Trial in COVID-19 Program
PR Newswire · 06/19 13:00
Ampio Says Filed IND Applications For Ampion
ENGLEWOOD, Colo., May 22, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for
Benzinga · 05/22 12:02